66110 Federal Register / Vol. 75, No. 207 / Wednesday, October 27, 2010 / Notices 

inflammatory response that results in 

fibrosis as seen in Crohn’s disease. 

Preventing the inflammatory response of 

colitis by either modulating or blocking 

IL–13 and NKT cell activity continues to 

be an effective therapeutic approach in 

animal models of colitis with 

implications for the treatment of human 

ulcerative colitis and for the treatment 

of fibrosis associated with Crohn’s 

disease. 

Inventors: Warren Strober (NIAID), 

Ivan J. Fuss (NIAID), Peter Mannon 

(NIAID), Jan Preiss (NIAID), Raj Puri 

(FDA), Koji Kawakami (FDA), Stefan 

Fichtner-Feigl (NIAID), Atsushi Kitani 

(NIAID). 

Related Publications: 

1. F Heller, IJ Fuss, EW Nieuwenhuis, 

RS Blumberg, W Strober. Oxazolone 

colitis, a Th2 colitis model resembling 

ulcerative colitis, is mediated by IL–13- 

producing NK–T cells. Immunity 2002 

Nov;17(5):629–628. [PubMed: 

12433369]. 

2. IJ Fuss, F Heller, M Boirivant, F 

Leon, M Yoshida, S Fichtner-Feigl, Z 

Yang, M Exley, A Kitani, RS Blumberg, 

P Mannon, W Strober. Nonclassical 

CD1d-restricted NK T cells that produce 

IL–13 characterize an atypical Th2 

response in ulcerative colitis. J Clin 

Invest. 2004 May 15;113(10):1490–1497. 

[PubMed: 15146247]. 

Patent Status: U.S. Patent Application 

No. 11/918,711 filed 14 Apr 2006 (HHS 

Reference No. E–003–2005/0–US–03) 

and related international filings. 

Related Technologies: 

• IL–13 modulators and inhibitors— 

U.S. Patent No. 7,666,411 issued 23 Feb 

2010 (HHS Reference No. 131–2002/0– 

US–02), U.S. Patent Application No. 12/ 

709,029 filed 19 Feb 2010 (HHS 

Reference No. E–131–2002/0–US–10), 

and related international filings. 

• NF-kappa B decoy 

oligonucleotides—U.S. Patent 

Application No. 11/920,214 filed 09 

Nov 2007 (HHS Reference No. E–108– 

2005/0–US–03). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Betty B. Tong, 

Ph.D.; 301–594–6565; 

tongb@mail.nih.gov. 

Dated: October 21, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–27177 Filed 10–26–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Guidelines for Use of Stored 

Specimens and Access to Ancillary 

Data and Proposed Cost Schedule: 

Stored Biologic Specimens and 

Ancillary Data From the Collaborative 

Perinatal Project (CPP) 

ACTION: Notice and request for 

comments. 

SUMMARY: The Division of 

Epidemiology, Statistics and Prevention 

Research (hereafter, Division) of the 

Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development (NICHD) maintains an 

extensive repository of datasets from 

completed studies, biospecimens, and 

ancillary data. The Division intends to 

make datasets and biospecimens more 

widely available to the research 

community for use by qualified 

researchers and to establish procedures 

for access consistent with the National 

Institutes of Health (NIH) Data Sharing 

Policy. The Division has established an 

internal committee, the Biospecimen 

Repository Access and Data Sharing 

Committee (BRADSC), to oversee the 

repository access and data sharing 

program. The purpose of this notice is 

to request comments on this program 

and present the initial proposed cost 

schedule. After full consideration of 

comments submitted in response to this 

notice, the BRADSC will finalize 

proposal guidelines and procedures, 

publish the cost schedule to the 

Division Web site, and begin to accept 

proposals for use of the stored biologic 

samples and for access to ancillary data 

that may not be available electronically. 

The first specimens and ancillary data 

that will be made available under this 

program are those from the national 

Collaborative Perinatal Project (CPP). 

The CPP is a large, prospective cohort 

study, conducted by the National 

Institute of Neurological Diseases and 

Stroke (NINDS) of the National 

Institutes of Health (NIH), which 

recruited and enrolled 48,197 women 

who contributed 54,390 pregnancies 

that were prospectively followed from 

1959–1966 at twelve academic medical 

centers across the United States. 

Custody for disposition of the CPP 

serum specimens was transferred to the 

Division from the NINDS in 1993 and 

for the microfiche archives in 1999. 

However, under the Federal Privacy Act 

of 1974 the samples and archive still 

belong to NINDS. Since 1992, the 

specimens have had limited public 

availability through Division 

investigators. Going forward, the 

Biospecimen Repository Access and 

Data Sharing Committee (BRADSC) will 

oversee the repository access and data 

sharing program. Access to other 

Division resources will be announced 

on the Division Web site. The BRADSC 

reserves the right to amend the 

procedures and costs schedules as 

necessary to maintain the integrity of 

the program and to suit the conditions 

under which other specimens were 

collected. Announcements and current 

proposal guidelines will be available 

under the Research link at http:// 

despr.nichd.nih.gov, and interested 

researchers should consult the Division 

Web site for resources available, the 

most recent guidelines for proposal 

submission and evaluation, and cost 

schedules. Procedures may vary 

depending on the age and nature of the 

samples and original institutional 

review board (IRB) approval, although 

the general outline of the procedures 

should remain the same. Cost schedules 

may vary depending on the nature and 

complexity of the request. 

No funding is provided as part of this 

notice nor will any be available as part 

of the program either to support 

laboratory analyses or data management. 

Samples will only be provided to 

approved projects upon receipt of 

evidence of necessary IRB approval(s), 

funding and payment of repository costs 

and shipping. Approved projects that do 

not obtain funding will be canceled 

within one year of their approval date. 

A more complete description of this 

program follows. Comments or requests 

for clarification on all aspects of the 

program are welcome. 

DATES: 

• Comment Receipt Date: December 

15, 2010. 

• Invitation to Submit Proposal: 

Proposals can be submitted on an 

ongoing basis. 

• Scientific Review Dates: Technical 

Panels for reviews will be assembled 

beginning on January 1, May 1, or 

September 1 of the calendar year so that 

proposals can be evaluated well in 

advance of Federal funding deadlines. 

• Anticipated Distribution of 

Samples: Within one month of 

demonstrable proof of applicant IRB 

approval and receipt of payment to 

cover repository costs and shipping. 

ADDRESSES: To send comments and to 

request information, contact: Dr. Mary 

L. Hediger, Division of Epidemiology, 

Statistics and Prevention Research, 

Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, 6100 Executive Blvd, 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 207 / Wednesday, October 27, 2010 / Notices 66111 

Room 7B03, MSC 7510, Rockville, MD 

20852, Phone: 301–435–6897, E-mail: 

hedigerm@exchange.nih.gov. 

SUPPLEMENTARY INFORMATION: 

The Collaborative Perinatal Project 

(CPP): The major stated aims of the CPP 

were to: (1) Determine the relationship 

between factors in the perinatal 

environment and the continuum of 

human reproductive failure, with 

particular reference to the central 

nervous system (CNS) for early (infancy 

and early childhood) and later 

(childhood) manifestations of deficits; 

(2) study the effect of the extra-uterine 

environment on fetal development (e.g., 

socio-economic factors, family 

structure); (3) determine the 

relationship of prematurity to factors in 

the perinatal environment and the 

continuum of human reproductive 

failure, with particular reference to the 

CNS; (4) study the clinico-pathological 

correlations in the continuum of human 

reproductive failure, with particular 

reference to the CNS; and (5) improve 

the classification, treatment and 

prevention of cerebral palsy. The 

Collaborative Perinatal Project (CPP) 

enrolled 48,197 women who 

contributed 54,390 pregnancies that 

were prospectively followed from 1959– 

1966 at twelve academic medical 

centers across the United States, 

including hospitals in Baltimore MD, 

Boston MA, Buffalo NY, Memphis TN, 

Minneapolis MN, New Orleans LA, New 

York NY (2 sites), Philadelphia PA, 

Providence RI, Portland OR, and 

Richmond VA. The women were 

recruited generally in the second 

trimester of pregnancy and followed 

through delivery. The children were 

followed periodically to seven or eight 

years of age. Data collection was 

concluded in 1974, and data were stored 

on computer tapes in ‘‘card image’’ 

format (80 columns/card). 

A wide range of data was collected 

using standardized protocols and forms, 

including socio-demographic, obstetric, 

pediatric, infant neurological, and child 

psychological information. Electronic 

data files, forms, and documentation are 

available and accessible in the public 

domain. The CPP collected serum 

samples at recruitment, every eight 

weeks thereafter during pregnancy, and 

at the time of the delivery 

hospitalization. Cord blood was 

collected from approximately 60 percent 

of the infants, and some serum samples 

are available from women at six weeks 

postpartum. Residual serum and cord 

blood samples have been stored 

continuously in glass vials at ¥20 °C 

since collection, are inventoried, and 

are linkable to individual electronic 

records by the original CPP 

identification number. A microfiche 

archive is also stored and available, 

compiled by identification number, and 

containing CPP completed forms and 

records with ancillary information, 

original medical notes, and comments. 

In 1983, electronic data files, forms, 

and documentation were compiled from 

the original tapes and manuals, 

documented, and written to other 

media. The data and documentation are 

currently available and accessible in the 

public domain (e.g., http:// 

www.nber.org/cpp/docs/). In addition to 

the files available electronically, the 

CPP collected serum samples at 

recruitment, subsequently every eight 

weeks during pregnancy, and at the time 

of the delivery hospitalization. Cord 

blood was collected from approximately 

60 percent of the infants, and some 

serum samples are available from 

women at six weeks postpartum. 

Residual serum and cord blood samples 

have been stored continuously in glass 

vials at ¥20 °C since collection, are 

inventoried, and are linkable to 

individual electronic records by the 

original CPP identification number. A 

microfiche archive, compiled by 

identification number containing CPP 

completed forms and records with 

ancillary information, original medical 

notes, and comments, is also stored and 

available. 

There are CPP serum samples from at 

least 53,515 pregnancies from 46,424 

women available for research proposals 

using CPP samples. There are 

approximately 32,130 samples of cord 

blood. 

Clinical Significance: Because the 

CPP samples were collected before 

controlling guidelines were available, 

participants did not consent to future 

use. Therefore, only research projects 

that propose laboratory results or 

findings in the ancillary data that do not 

have immediate clinical significance to 

an individual will be deemed acceptable 

for the CPP. Applicants should address 

this clearly in the research proposal. 

Clinical significance for laboratory 

studies is defined by the following 

criteria: 

The findings are valid and done by a 

CLIA-certified laboratory; and 

The findings may have significant 

immediate implications for the 

subjects’ health concerns; and 

A course of action to ameliorate, or treat 

the concerns is readily available. 

Clinical significance for ancillary 

findings is defined: 

The findings may have significant 

immediate implications for the 

subjects’ or their family’s health 

concerns; and 

A course of action to ameliorate, or treat 

the concerns is readily available. 

Proposals for Use of the Samples and 

Access to the Ancillary Data: All 

proposals for use of CPP samples and 

access to the ancillary data will be 

evaluated by an ad hoc Technical Panel 

for scientific merit. The BRADSC will 

generally rely on the investigators’ 

approval of the proposal by their 

institutional review board (IRB) for use 

of the samples and access, although the 

BRADSC reserves the right in 

questionable cases to have the NICHD 

IRB review the proposal even if the 

investigators have already received 

approval by their IRB. 

Evaluation Criteria: To determine if 

the biologic specimens (a limited 

resource) should be used in the 

proposed projects or if an applicant 

should be given access to the microfiche 

archives, an ad hoc Technical Panel, 

chosen and overseen by BRADSC and 

comprised of two content and one 

statistical reviewer, will evaluate the 

public health significance and scientific 

merit of each proposed research project. 

Applicants may be asked to suggest 

outside reviewers, but the final 

composition of the Technical Panel will 

be at the discretion of the BRADSC. 

Scientific merit will be judged as to the 

scientific, technical or medical 

significance of the research, the 

appropriateness and adequacy of the 

experimental approach, and the 

methodology proposed to reach the 

research goals. If the project involves 

biologic specimens, the Technical Panel 

will also consider the amount of sample 

requested and weigh the significance of 

the research against the amount of 

sample requested and that remaining. 

Investigators are encouraged to request 

the smallest amount of sample possible 

consistent with best scientific practices 

and the aims of their study. The 

proposal should outline how the results 

from the laboratory analysis or findings 

from the original forms will be used. 

The appropriateness of the CPP sample 

to address the goals of the proposal will 

be an important aspect of scientific 

merit. The Technical Panel will review 

the analysis plan and evaluate whether 

the proposal is an appropriate use of the 

CPP population and likely to be 

successful. The Technical Panel will 

also assure that the proposed project 

does not go beyond the specific stated 

goals of the proposal. Investigators are 

encouraged to review the CPP forms and 

documentation at: http:// 

despr.nichd.nih.gov or http:// 

www.nber.org/cpp/docs/. The Division 

Web site will also have posted 


srobinson on DSKHWCL6B1PROD with NOTICES
66112 Federal Register / Vol. 75, No. 207 / Wednesday, October 27, 2010 / Notices 

accessible copies of pertinent 

publications on the history of the CPP 

and scientific papers with notable 

findings. 

Procedures for Proposals: All 

investigators (including NIH and NICHD 

investigators) must submit a proposal 

for use of CPP specimens. Proposals are 

limited to a maximum of ten (10) singlespaced typed pages, excluding figures 

and tables, using 12 cpi type density. 

The proposal should be comprehensive 

and tailored to the request and not 

simply be sections lifted from another 

Federal or foundation application. The 

cover of the proposal should include the 

name, address, and phone number and 

e-mail address of the Principal 

Investigator (PI) and the name of the 

institution where the laboratory analysis 

will be done if they are a component of 

the project. All proposals should be emailed to the address specified on the 

Web site. Proposals must include a 

cover page with the title of the proposal 

and the name, address, phone number 

and e-mail address of all investigators. 

The following criteria will be used for 

technical evaluation of proposals: 

Proposals should include the 

following information: 

(1) Specific Aims: List the broad 

objectives; describe concisely and 

realistically what the research is 

intended to accomplish, and state the 

specific hypotheses to be tested. 

(2) Background and Public Health 

Significance: Describe the public health 

significance, scientific merit and 

practical utility of the assay or 

information. Briefly describe in one or 

two pages the background of the 

proposal, identifying how the project 

may also relate to previous (published) 

analyses of the CPP and gaps in 

knowledge that the project is intended 

to fill. State concisely the importance of 

the research in terms of the broad, longterm objectives and public health 

relevance including a discussion of how 

the results will affect public health 

policy or further scientific knowledge. 

The proposer should convey how the 

results will be used and the relationship 

of the results to the data already 

collected in the CPP. The applicant 

should include an analysis plan. 

Applicants are encouraged strongly to 

have a statistical consultant or someone 

knowledgeable about statistics be part of 

the investigative team or nominally 

review the plan before submission. The 

analyses ought to be consistent broadly 

with the CPP aims and the health status 

variables. 

(3) Research Design and Methods: 

Describe the research design and the 

procedures to be used. Data and/or 

biospecimen requests should specify the 

exact variable(s) or sample name(s) as 

provided in the CPP documentation or 

give an expectation of findings in notes 

or other forms in the microfiche archive. 

If there is a laboratory component, a 

detailed description of laboratory 

methods including validity and 

reliability must be included with 

references. Because the samples were 

collected over forty years ago, 

applicants should consider how aging 

might have affected the samples. If no 

data are available on how aging might 

have affected the samples, a limited 

number of samples of the same 

historical age are available for pilot 

studies. Even if the proposal is 

meritorious, the BRADSC may expect, 

upon advice of the Technical Panel, that 

a pilot be completed before all 

specimens requested are released to the 

investigators. 

The volume of specimen and number 

of samples requested must be specified. 

Adequate methods for handling and 

storage of samples must also be 

addressed. The laboratory must 

demonstrate expertise in the proposed 

laboratory test including the capability 

for handling the workload requested in 

the proposal. The proposal should also 

include a justification for determination 

of study sample size or a power 

calculation. If the researcher is 

requesting a regional or targeted subsample of specimens, a detailed 

description and justification must be 

given. The study design and analysis 

plan in the proposal will be evaluated 

to determine whether the project is 

feasible and can be performed using the 

CPP. 

(4) Clinical Significance or Results: 

Since individual results cannot be 

provided, the clinical significance of the 

proposed laboratory test should be 

addressed. The proposal should include 

a discussion of the potential clinical 

significance of the results and whether 

there is definitive evidence that results 

of the test would provide grounds for 

medical intervention even given that 

many years have passed since the 

examination of the participant and 

collection of the sample. Any test with 

results that should be reported 

immediately to a participant is not 

appropriate for testing on the stored 

samples. 

(5) Qualifications: Provide a brief 

description of the Principal Investigator 

and other investigators’ expertise in the 

proposed area, including publications in 

this area within the last three years. A 

representative sample of earlier 

publications may be listed as long as 

this section does not exceed two pages. 

(6) Period of performance: Specify the 

project period. Substantial progress 

must be made in the first year, and the 

project should be completed in two 

years. If additional time is needed for 

the research project a detailed 

justification with a timeline should be 

included. The investigators should 

address their ability to comply with this 

timeline or request and justify 

additional time for the project. Return of 

the specimens will be requested if 

progress is not made in the project at the 

end of the second year. Refund of 

payment for the specimens will not be 

returned in this situation. At the end of 

the project period, any unused samples 

must be returned to the Division 

Repository or discarded, according to 

the wishes of the BRADSC. Within six 

months to one year of the end of the 

project period, and consistent with NIH 

Data Sharing guidelines, the 

investigators will submit to the Division 

for access by the wider research 

community a complete and clean copy 

of the new data obtained, whether from 

laboratory analyses or the microfiche 

archives, coded and linkable to the main 

CPP database through the study ID, 

documentation, and a letter from the PI 

certifying the data. 

(7) Funding: Include the source and 

status of the funding to perform the 

requested laboratory analysis should be 

included. Investigators will be 

responsible for the cost of processing 

and shipping the samples. The basis for 

the cost structure is in the last section 

of this notice. Reimbursement for the 

samples will be collected before the 

samples are released. 

Submission of Proposals: Proposals 

can be submitted in MS Word or pdf 

format by e-mail to: 

hedigerm@exchange.nih.gov. 

Summary of Evaluation Criteria: (1) 

Relevance of the study question to 

current research; (2) adequacy of the 

study design to address the question; (3) 

feasibility and appropriateness of the 

CPP for conducting the study; (4) if 

there is a laboratory component, 

appropriateness of the assay, including 

evidence that the analyte is stable under 

prolonged storage at ¥20 °C; and (5) 

experience of the investigators in 

conducting similar studies, including 

knowledge of the CPP. 

Approved Proposals: Approved 

projects will be provided specimens 

upon receipt of a check to cover the cost 

of accessing, preparing, and shipping 

the specimens. Approved projects 

requesting access to the microfiche 

archives will be granted access once 

arrangements have been made with the 

Division. Approved and funded projects 

will be posted by title and abstract on 

the Division Web site once specimens 

have been shipped. Note that 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 207 / Wednesday, October 27, 2010 / Notices 66113 

biospecimens will be distributed 

blinded, that is, with an identifier that 

will only be linked to the study 

identification number upon completion 

of laboratory analyses, unless 

arrangements have been made for 

interim analyses beforehand. 

Progress Reports: Brief progress 

reports must be submitted annually to 

judge progress. 

Disposition of Results and Samples: 

No samples provided can be used for 

any purpose other than those 

specifically requested in the proposal 

and approved by the Technical Panel. 

No sample can be shared with others, 

including other investigators, unless 

specified in the proposal and so 

approved. Any unused samples must be 

either discarded or returned to the 

Division Repository, according to the 

wishes of the BRADSC upon completion 

of the approved project. 

Proposed Cost Schedule for Providing 

CPP Specimens: A nominal processing 

fee of approximately $8.00–$16.00 per 

sample, plus express shipping costs is 

anticipated for each sample requested 

and received. Costs will be fully 

estimated at the time of proposal 

acceptance and will take into 

consideration time and materials for the 

collection, storage and processing of the 

specimens by the Division Repository 

along with the preparation of the 

accompanying data files. The material 

costs are for the recurring laboratory 

costs to dispense and prepare the 

samples during collection and the 

computer software needed for the 

preparation of the data files. Because 

size of the shipments and distance to 

laboratories may vary, shipping costs 

will be estimated at the time of proposal 

acceptance. Cost reimbursement 

structures negotiated and accepted as 

part of a final proposal acceptance will 

be honored for one year from the date 

of proposal acceptance. 

Proposed Cost for Accessing CPP 

Microfiche Archives: There is no direct 

cost for accessing the CPP microfiche 

archives, although arrangements will 

have to be made for access to the 

building and is dependent upon the 

space available to accommodate a 

researcher. 

As additional specimens and 

resources from Division projects are 

made available for public use, 

announcements will be made on the 

Division Web site without further 

announcement in the Federal Register. 

As a reminder, the BRADSC and 

Division reserve the right to amend the 

proposal guidelines and cost schedule 

as needed and in keeping with the 

nature and complexity of the applicants’ 

request. 

Dated: October 20, 2010. 

Germaine M. Buck Louis, 

Director and Senior Investigator, Division of 

Epidemiology, Statistics, and Prevention 

Research, Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development. 

[FR Doc. 2010–27183 Filed 10–26–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

NRSA Institutional Research Training (T32). 

Date: November 17, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Ave., NW., Washington, DC 20037. 

Contact Person: Aileen Schulte, PhD, 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd, Room 6140, MSC 9608, 

Bethesda, MD 20892–9608, 301–443–1225, 

aschulte@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Novel NeuroAIDS Therapeutics. 

Date: November 22, 2010. 

Time: 12 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: David W Miller, PhD, 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd., Room 6140, MSC 9608, 

Bethesda, MD 20892–9608, 301–443–9734, 

millerda@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: October 20, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–27186 Filed 10–26–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Small 

Business: Skeletal Muscle and Exercise 

Physiology. 

Date: November 10–11, 2010. 

Time: 9 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting) 

Contact Person: Richard Ingraham, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4116, 

MSC 7814, Bethesda, MD 20892, 301–496– 

8551, ingrahamrh@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, RFA Panel: 

Developmental Pharmacology. 

Date: December 6–7, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting) 

Contact Person: Janet M Larkin, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 


srobinson on DSKHWCL6B1PROD with NOTICES